Theme II: Fungal components as antifungal drug targets, diagnostics, vaccine antigens and adjuvants

Our relocation to Exeter has offered tremendous opportunities for substantially enhancing our early and late-stage research into the identification, development and exploitation of fungal components for diagnostic, therapeutic and translational uses. Under this theme, key areas include the development of high throughput and other in vitro and in vivo approaches to identify and validate novel antifungal drug targets; antifungal drug discovery (including studies with Blueberry Therapeutics, Syngenta, Medchemica and LifeArc); mode of action drug studies (including those with Gilead); as well as development and commercialisation of antifungal antibodies for diagnostic and therapeutic use.